Pfizer Inc and BioNTech SE announced positive results from their phase 3 clinical trial that assessed a combined mRNA vaccine candidate to protect against influenza and COVID-19 among healthy individuals aged 18 to 64 years. According to study authors, the combination includes Pfizer’s mRNA-based influenza vaccine with the licensed COVID-19 vaccine.1
“We are encouraged by the robust immunogenicity we saw with our combination vaccine against influenza A, which was similar to what we had seen for our initial quadrivalent influenza vaccine where we saw superior relative vaccine efficacy against a comparator flu vaccine,” Annaliesa Anderson, PhD, senior vice president and head of vaccine research and development at Pfizer, said in a news release.1
Influenza is reported to cause around 140,000 to 710,00 hospitalizations and 12,000 to 52,000 deaths in the US each year.1 The virus contains 4 types of infection, including A, B, C, and D; however A and B cause the seasonal epidemics of the disease, recognized as flu season. Study authors noted that influenza A viruses are separated into subtypes based on 2 proteins on the exterior of the virus—hemagglutinin (H) and neuraminidase (N), with 18 different H subtypes and 11 different N subtypes.2
Individuals 65 years and older face an increased risk of hospitalization and death caused from influenza, despite receiving a vaccine that matches the circulating strain. Study authors noted that available influenza vaccines provide 40% to 60% protection annually and is decreasing protection in years with poor corresponding of strains.1
However, because influenza strains change within the seasons, researchers noted that it becomes difficult to match the vaccine for the upcoming epidemics, which are typically chosen more than 6 months before the next season. mRNA technology could solve this issue due to its prompt manufacturing, allowing for a more accurate strain match.1